 |
9 Products |  |
120 Diseases | | 9 Products |
|
46 Trials |  |
2133 News |  |
| «12...1011121314151617181920...2930» |
- Campath (alemtuzumab) / Sanofi
[VIRTUAL] OUTCOMES OF HAEMATOPOIETIC STEM CELL TRANSPLANTATION IN CHILDREN WITH ZETA CHAIN ASSOCIATED PROTEIN KINASE 70KDA DEFICIENCY (ePoster Area) - Feb 4, 2021 - Abstract #EBMT2021EBMT_2867;
Conditioning was busulfan-cyclosphosphamide±alemtuzumab (n=3), fludarabine-melphalan+alemtuzumab (n=1), fludarabine-treosulfan+alemtuzumab (n=4) fludarabine-treosulfan-thioterapa-ATG-rituximab (n=1, TCRab/CD19 depleted parental graft).Median time to neutrophil engraftment was 14 days (8 – 28) and median time to platelet engraftment was 24 days (4 - 44)...One had post-transplant autoimmune cytopenia requiring steroid, high dose immunoglobulin (Ig), rituximab, MMF and sirolimus... In our centre, transplant outcomes for ZAP70 deficiency are excellent.
- Campath (alemtuzumab) / Sanofi
[VIRTUAL] OUTCOMES OF HAEMATOPOIETIC STEM CELL TRANSPLANTATION IN CHILDREN WITH ZETA CHAIN ASSOCIATED PROTEIN KINASE 70KDA DEFICIENCY (ePoster Area) - Feb 4, 2021 - Abstract #EBMT2021EBMT_2866;
Conditioning was busulfan-cyclosphosphamide±alemtuzumab (n=3), fludarabine-melphalan+alemtuzumab (n=1), fludarabine-treosulfan+alemtuzumab (n=4) fludarabine-treosulfan-thioterapa-ATG-rituximab (n=1, TCRab/CD19 depleted parental graft).Median time to neutrophil engraftment was 14 days (8 – 28) and median time to platelet engraftment was 24 days (4 - 44)...One had post-transplant autoimmune cytopenia requiring steroid, high dose immunoglobulin (Ig), rituximab, MMF and sirolimus... In our centre, transplant outcomes for ZAP70 deficiency are excellent. Conditioning was busulfan-cyclosphosphamide±alemtuzumab (n=3), fludarabine-melphalan+alemtuzumab (n=1), fludarabine-treosulfan+alemtuzumab (n=4) fludarabine-treosulfan-thioterapa-ATG-rituximab (n=1, TCRab/CD19 depleted parental graft).Median time to neutrophil engraftment was 14 days (8 – 28) and median time to platelet engraftment was 24 days (4 - 44)...One had post-transplant autoimmune cytopenia requiring steroid, high dose immunoglobulin (Ig), rituximab, MMF and sirolimus... In our centre, transplant outcomes for ZAP70 deficiency are excellent.
- Campath (alemtuzumab) / Sanofi
[VIRTUAL] OUTCOMES OF HAEMATOPOIETIC STEM CELL TRANSPLANTATION IN CHILDREN WITH ZETA CHAIN ASSOCIATED PROTEIN KINASE 70KDA DEFICIENCY (ePoster Area) - Feb 4, 2021 - Abstract #EBMT2021EBMT_2865;
Conditioning was busulfan-cyclosphosphamide±alemtuzumab (n=3), fludarabine-melphalan+alemtuzumab (n=1), fludarabine-treosulfan+alemtuzumab (n=4) fludarabine-treosulfan-thioterapa-ATG-rituximab (n=1, TCRab/CD19 depleted parental graft).Median time to neutrophil engraftment was 14 days (8 – 28) and median time to platelet engraftment was 24 days (4 - 44)...One had post-transplant autoimmune cytopenia requiring steroid, high dose immunoglobulin (Ig), rituximab, MMF and sirolimus... In our centre, transplant outcomes for ZAP70 deficiency are excellent. Conditioning was busulfan-cyclosphosphamide±alemtuzumab (n=3), fludarabine-melphalan+alemtuzumab (n=1), fludarabine-treosulfan+alemtuzumab (n=4) fludarabine-treosulfan-thioterapa-ATG-rituximab (n=1, TCRab/CD19 depleted parental graft).Median time to neutrophil engraftment was 14 days (8 – 28) and median time to platelet engraftment was 24 days (4 - 44)...One had post-transplant autoimmune cytopenia requiring steroid, high dose immunoglobulin (Ig), rituximab, MMF and sirolimus... In our centre, transplant outcomes for ZAP70 deficiency are excellent.
- Campath (alemtuzumab) / Sanofi
[VIRTUAL] OUTCOMES OF HAEMATOPOIETIC STEM CELL TRANSPLANTATION IN CHILDREN WITH ZETA CHAIN ASSOCIATED PROTEIN KINASE 70KDA DEFICIENCY (ePoster Area) - Feb 4, 2021 - Abstract #EBMT2021EBMT_2864;
Conditioning was busulfan-cyclosphosphamide±alemtuzumab (n=3), fludarabine-melphalan+alemtuzumab (n=1), fludarabine-treosulfan+alemtuzumab (n=4) fludarabine-treosulfan-thioterapa-ATG-rituximab (n=1, TCRab/CD19 depleted parental graft).Median time to neutrophil engraftment was 14 days (8 – 28) and median time to platelet engraftment was 24 days (4 - 44)...One had post-transplant autoimmune cytopenia requiring steroid, high dose immunoglobulin (Ig), rituximab, MMF and sirolimus... In our centre, transplant outcomes for ZAP70 deficiency are excellent. Conditioning was busulfan-cyclosphosphamide±alemtuzumab (n=3), fludarabine-melphalan+alemtuzumab (n=1), fludarabine-treosulfan+alemtuzumab (n=4) fludarabine-treosulfan-thioterapa-ATG-rituximab (n=1, TCRab/CD19 depleted parental graft).Median time to neutrophil engraftment was 14 days (8 – 28) and median time to platelet engraftment was 24 days (4 - 44)...One had post-transplant autoimmune cytopenia requiring steroid, high dose immunoglobulin (Ig), rituximab, MMF and sirolimus... In our centre, transplant outcomes for ZAP70 deficiency are excellent.
- Campath (alemtuzumab) / Sanofi
[VIRTUAL] CLINICAL MANIFESTATION AND MECHANISMS OF GRAFT FAILURE IN PRIMARY IMMUNODEFICIENCY PATIENTS AFTER HEMATOPOIETIC STEM CELL TRANSPLANTATION (ePoster Area) - Feb 4, 2021 - Abstract #EBMT2021EBMT_2863;
Chimerism analysis (increasing recipient T cells vs recipient myeloid cells) suggests that early and late GF may have different mechanisms. Early GF is often associated with HS.
- Campath (alemtuzumab) / Sanofi
[VIRTUAL] CLINICAL MANIFESTATION AND MECHANISMS OF GRAFT FAILURE IN PRIMARY IMMUNODEFICIENCY PATIENTS AFTER HEMATOPOIETIC STEM CELL TRANSPLANTATION (ePoster Area) - Feb 4, 2021 - Abstract #EBMT2021EBMT_2862;
Chimerism analysis (increasing recipient T cells vs recipient myeloid cells) suggests that early and late GF may have different mechanisms. Early GF is often associated with HS.
- Campath (alemtuzumab) / Sanofi
[VIRTUAL] CLINICAL MANIFESTATION AND MECHANISMS OF GRAFT FAILURE IN PRIMARY IMMUNODEFICIENCY PATIENTS AFTER HEMATOPOIETIC STEM CELL TRANSPLANTATION (ePoster Area) - Feb 4, 2021 - Abstract #EBMT2021EBMT_2861;
Chimerism analysis (increasing recipient T cells vs recipient myeloid cells) suggests that early and late GF may have different mechanisms. Early GF is often associated with HS.
- Campath (alemtuzumab) / Sanofi
[VIRTUAL] CLINICAL MANIFESTATION AND MECHANISMS OF GRAFT FAILURE IN PRIMARY IMMUNODEFICIENCY PATIENTS AFTER HEMATOPOIETIC STEM CELL TRANSPLANTATION (ePoster Area) - Feb 4, 2021 - Abstract #EBMT2021EBMT_2860;
Chimerism analysis (increasing recipient T cells vs recipient myeloid cells) suggests that early and late GF may have different mechanisms. Early GF is often associated with HS.
- Ovastat (treosulfan) / Medac
[VIRTUAL] HEMATOPOIETIC STEM CELL TRANSPLANTATION IN CHILDREN WITH NEUTROPHIL DISORDERS (ePoster Area) - Feb 4, 2021 - Abstract #EBMT2021EBMT_2763;
Myeloablative conditioning results in engraftment with an overall survival of 80%. Haploidentical HSCT using TCR alpha beta depletion is safe in infants with neutrophil disorders and hence early HSCT can be offered with optimal outcomes.
- Ovastat (treosulfan) / Medac
[VIRTUAL] HEMATOPOIETIC STEM CELL TRANSPLANTATION IN CHILDREN WITH NEUTROPHIL DISORDERS (ePoster Area) - Feb 4, 2021 - Abstract #EBMT2021EBMT_2762;
Myeloablative conditioning results in engraftment with an overall survival of 80%. Haploidentical HSCT using TCR alpha beta depletion is safe in infants with neutrophil disorders and hence early HSCT can be offered with optimal outcomes.
- Ovastat (treosulfan) / Medac
[VIRTUAL] HEMATOPOIETIC STEM CELL TRANSPLANTATION IN CHILDREN WITH NEUTROPHIL DISORDERS (ePoster Area) - Feb 4, 2021 - Abstract #EBMT2021EBMT_2761;
Myeloablative conditioning results in engraftment with an overall survival of 80%. Haploidentical HSCT using TCR alpha beta depletion is safe in infants with neutrophil disorders and hence early HSCT can be offered with optimal outcomes.
- Ovastat (treosulfan) / Medac
[VIRTUAL] HEMATOPOIETIC STEM CELL TRANSPLANTATION IN CHILDREN WITH NEUTROPHIL DISORDERS (ePoster Area) - Feb 4, 2021 - Abstract #EBMT2021EBMT_2760;
Myeloablative conditioning results in engraftment with an overall survival of 80%. Haploidentical HSCT using TCR alpha beta depletion is safe in infants with neutrophil disorders and hence early HSCT can be offered with optimal outcomes.
- Ovastat (treosulfan) / Medac
[VIRTUAL] ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION IN PATIENTS OLDER THAN 65 YEARS WITH AML AND MDS: RISK FACTORS FOR OVERALL SURVIVAL AND DISEASE FREE SURVIVAL (ePoster Area) - Feb 4, 2021 - Abstract #EBMT2021EBMT_2743;
HCT-CI is an important tool to help in selecting those patients more likely to benefit from allo-HCT. HLA matched donor (sibling and unrelated) with PTCy as GvHD prophylaxis improved both OS and DFS compared to ATG.
- Ovastat (treosulfan) / Medac
[VIRTUAL] ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION IN PATIENTS OLDER THAN 65 YEARS WITH AML AND MDS: RISK FACTORS FOR OVERALL SURVIVAL AND DISEASE FREE SURVIVAL (ePoster Area) - Feb 4, 2021 - Abstract #EBMT2021EBMT_2742;
HCT-CI is an important tool to help in selecting those patients more likely to benefit from allo-HCT. HLA matched donor (sibling and unrelated) with PTCy as GvHD prophylaxis improved both OS and DFS compared to ATG.
- Ovastat (treosulfan) / Medac
[VIRTUAL] ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION IN PATIENTS OLDER THAN 65 YEARS WITH AML AND MDS: RISK FACTORS FOR OVERALL SURVIVAL AND DISEASE FREE SURVIVAL (ePoster Area) - Feb 4, 2021 - Abstract #EBMT2021EBMT_2741;
HCT-CI is an important tool to help in selecting those patients more likely to benefit from allo-HCT. HLA matched donor (sibling and unrelated) with PTCy as GvHD prophylaxis improved both OS and DFS compared to ATG.
- Ovastat (treosulfan) / Medac
[VIRTUAL] ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION IN PATIENTS OLDER THAN 65 YEARS WITH AML AND MDS: RISK FACTORS FOR OVERALL SURVIVAL AND DISEASE FREE SURVIVAL (ePoster Area) - Feb 4, 2021 - Abstract #EBMT2021EBMT_2740;
HCT-CI is an important tool to help in selecting those patients more likely to benefit from allo-HCT. HLA matched donor (sibling and unrelated) with PTCy as GvHD prophylaxis improved both OS and DFS compared to ATG.
- Ovastat (treosulfan) / Medac
[VIRTUAL] OUTCOME OF SECOND ALLOGENIC STEM CELL TRANSPLANTATION IN CHILDREN WITH PRIMARY IMMUNE DEFICIENCIES (ePoster Area) - Feb 4, 2021 - Abstract #EBMT2021EBMT_2731;
OS has improved in the last decade (93%) due to using advanced methods. Haploidentical TCR ab/CD19 depletion is an advanced cost-benefit rescue therapy which can be used if no matched donor is available.
- Ovastat (treosulfan) / Medac
[VIRTUAL] OUTCOME OF SECOND ALLOGENIC STEM CELL TRANSPLANTATION IN CHILDREN WITH PRIMARY IMMUNE DEFICIENCIES (ePoster Area) - Feb 4, 2021 - Abstract #EBMT2021EBMT_2730;
OS has improved in the last decade (93%) due to using advanced methods. Haploidentical TCR ab/CD19 depletion is an advanced cost-benefit rescue therapy which can be used if no matched donor is available.
- Ovastat (treosulfan) / Medac
[VIRTUAL] OUTCOME OF SECOND ALLOGENIC STEM CELL TRANSPLANTATION IN CHILDREN WITH PRIMARY IMMUNE DEFICIENCIES (ePoster Area) - Feb 4, 2021 - Abstract #EBMT2021EBMT_2729;
OS has improved in the last decade (93%) due to using advanced methods. Haploidentical TCR ab/CD19 depletion is an advanced cost-benefit rescue therapy which can be used if no matched donor is available.
- Ovastat (treosulfan) / Medac
[VIRTUAL] OUTCOME OF SECOND ALLOGENIC STEM CELL TRANSPLANTATION IN CHILDREN WITH PRIMARY IMMUNE DEFICIENCIES (ePoster Area) - Feb 4, 2021 - Abstract #EBMT2021EBMT_2728;
OS has improved in the last decade (93%) due to using advanced methods. Haploidentical TCR ab/CD19 depletion is an advanced cost-benefit rescue therapy which can be used if no matched donor is available.
- [VIRTUAL] SEVERE REFRACTORY SKIN GVHD IN CHILDREN: SERIES OF CLINICAL CASES (ePoster Area) - Feb 4, 2021 - Abstract #EBMT2021EBMT_2691;
Все пациенты умерли из-за инфекционных осложнений лечения. Комбинация иммуносупрессивных препаратов может помочь в лечении РТПХ, но пациенты страдают от побочных эффектов терапии, таких как токсичность, аплазия крови и т.д.
- [VIRTUAL] SEVERE REFRACTORY SKIN GVHD IN CHILDREN: SERIES OF CLINICAL CASES (ePoster Area) - Feb 4, 2021 - Abstract #EBMT2021EBMT_2690;
Все пациенты умерли из-за инфекционных осложнений лечения. Комбинация иммуносупрессивных препаратов может помочь в лечении РТПХ, но пациенты страдают от побочных эффектов терапии, таких как токсичность, аплазия крови и т.д.
- [VIRTUAL] SEVERE REFRACTORY SKIN GVHD IN CHILDREN: SERIES OF CLINICAL CASES (ePoster Area) - Feb 4, 2021 - Abstract #EBMT2021EBMT_2689;
All patients died due to infectious complications of the treatment. A combination of immunosuppressive drugs may help treat GVHD, but patients suffer from side effects of therapy such as toxicity, blood aplasia, etc.
- [VIRTUAL] SEVERE REFRACTORY SKIN GVHD IN CHILDREN: SERIES OF CLINICAL CASES (ePoster Area) - Feb 4, 2021 - Abstract #EBMT2021EBMT_2688;
Все пациенты умерли из-за инфекционных осложнений лечения. Комбинация иммуносупрессивных препаратов может помочь в лечении РТПХ, но пациенты страдают от побочных эффектов терапии, таких как токсичность, аплазия крови и т.д.
- Ovastat (treosulfan) / Medac
[VIRTUAL] PRE-TRANSPLANTATION PLASMA VITAMIN D LEVELS AND ACUTE GRAFT-VERSUS-HOST DISEASE AFTER MYELOABLATIVE ALLOGENEIC HEMATOPOIETIC CELL TRANSPLANTATION (ePoster Area) - Feb 4, 2021 - Abstract #EBMT2021EBMT_2687;
We found no support for an association between pre-transplantation vitamin D levels or vitamin D insufficiency and acute GvHD in patients receiving myeloablative conditioning. Our findings suggest that peri-transplantation vitamin D supplementation is unlikely to reduce the incidence of acute GvHD after myeloablative allogeneic transplantation in adults.
- Ovastat (treosulfan) / Medac
[VIRTUAL] PRE-TRANSPLANTATION PLASMA VITAMIN D LEVELS AND ACUTE GRAFT-VERSUS-HOST DISEASE AFTER MYELOABLATIVE ALLOGENEIC HEMATOPOIETIC CELL TRANSPLANTATION (ePoster Area) - Feb 4, 2021 - Abstract #EBMT2021EBMT_2686;
We found no support for an association between pre-transplantation vitamin D levels or vitamin D insufficiency and acute GvHD in patients receiving myeloablative conditioning. Our findings suggest that peri-transplantation vitamin D supplementation is unlikely to reduce the incidence of acute GvHD after myeloablative allogeneic transplantation in adults.
- Ovastat (treosulfan) / Medac
[VIRTUAL] PRE-TRANSPLANTATION PLASMA VITAMIN D LEVELS AND ACUTE GRAFT-VERSUS-HOST DISEASE AFTER MYELOABLATIVE ALLOGENEIC HEMATOPOIETIC CELL TRANSPLANTATION (ePoster Area) - Feb 4, 2021 - Abstract #EBMT2021EBMT_2685;
We found no support for an association between pre-transplantation vitamin D levels or vitamin D insufficiency and acute GvHD in patients receiving myeloablative conditioning. Our findings suggest that peri-transplantation vitamin D supplementation is unlikely to reduce the incidence of acute GvHD after myeloablative allogeneic transplantation in adults.
- Ovastat (treosulfan) / Medac
[VIRTUAL] PRE-TRANSPLANTATION PLASMA VITAMIN D LEVELS AND ACUTE GRAFT-VERSUS-HOST DISEASE AFTER MYELOABLATIVE ALLOGENEIC HEMATOPOIETIC CELL TRANSPLANTATION (ePoster Area) - Feb 4, 2021 - Abstract #EBMT2021EBMT_2684;
We found no support for an association between pre-transplantation vitamin D levels or vitamin D insufficiency and acute GvHD in patients receiving myeloablative conditioning. Our findings suggest that peri-transplantation vitamin D supplementation is unlikely to reduce the incidence of acute GvHD after myeloablative allogeneic transplantation in adults.
- Ovastat (treosulfan) / Medac
[VIRTUAL] TREOSULFAN VS. BUSULFAN-BASED REGIMENS IN PEDIATRIC PATIENTS: A 7-YEAR RETROSPECTIVE STUDY (ePoster Area) - Feb 4, 2021 - Abstract #EBMT2021EBMT_2559;
Our findings suggest that peri-transplantation vitamin D supplementation is unlikely to reduce the incidence of acute GvHD after myeloablative allogeneic transplantation in adults. In our institution, busulfan-based conditionings are more frequently used for children undergoing allogenic HSCT, but treosulfan-based conditioning is gaining acceptance.Treosulfan-based conditionings also showed a significantly lower frequency of aGVHD in malignant diseases.
- Ovastat (treosulfan) / Medac
[VIRTUAL] TREOSULFAN VS. BUSULFAN-BASED REGIMENS IN PEDIATRIC PATIENTS: A 7-YEAR RETROSPECTIVE STUDY (ePoster Area) - Feb 4, 2021 - Abstract #EBMT2021EBMT_2558;
In our institution, busulfan-based conditionings are more frequently used for children undergoing allogenic HSCT, but treosulfan-based conditioning is gaining acceptance.Treosulfan-based conditionings also showed a significantly lower frequency of aGVHD in malignant diseases. In our institution, busulfan-based conditionings are more frequently used for children undergoing allogenic HSCT, but treosulfan-based conditioning is gaining acceptance.Treosulfan-based conditionings also showed a significantly lower frequency of aGVHD in malignant diseases.
- Ovastat (treosulfan) / Medac
[VIRTUAL] TREOSULFAN VS. BUSULFAN-BASED REGIMENS IN PEDIATRIC PATIENTS: A 7-YEAR RETROSPECTIVE STUDY (ePoster Area) - Feb 4, 2021 - Abstract #EBMT2021EBMT_2557;
In our institution, busulfan-based conditionings are more frequently used for children undergoing allogenic HSCT, but treosulfan-based conditioning is gaining acceptance.Treosulfan-based conditionings also showed a significantly lower frequency of aGVHD in malignant diseases. In our institution, busulfan-based conditionings are more frequently used for children undergoing allogenic HSCT, but treosulfan-based conditioning is gaining acceptance.Treosulfan-based conditionings also showed a significantly lower frequency of aGVHD in malignant diseases.
- Ovastat (treosulfan) / Medac
[VIRTUAL] TREOSULFAN VS. BUSULFAN-BASED REGIMENS IN PEDIATRIC PATIENTS: A 7-YEAR RETROSPECTIVE STUDY (ePoster Area) - Feb 4, 2021 - Abstract #EBMT2021EBMT_2556;
In our institution, busulfan-based conditionings are more frequently used for children undergoing allogenic HSCT, but treosulfan-based conditioning is gaining acceptance.Treosulfan-based conditionings also showed a significantly lower frequency of aGVHD in malignant diseases. In our institution, busulfan-based conditionings are more frequently used for children undergoing allogenic HSCT, but treosulfan-based conditioning is gaining acceptance.Treosulfan-based conditionings also showed a significantly lower frequency of aGVHD in malignant diseases.
- Ovastat (treosulfan) / Medac
[VIRTUAL] LONG-TERM SAFETY AND EFFICACY OF A MYELOABLATIVE CONDITIONING REGIMEN OF REDUCED TOXICITY IN ALLOGENEIC HEMATOPOIETIC CELL TRANSPLANTATION (ePoster Area) - Feb 4, 2021 - Abstract #EBMT2021EBMT_2555;
Our real-world study confirms that alloHCT with FluTreo expands the transplant population with outcomes comparable to other myeloablative conditionings, even in secondary AML. The choice of alloHCT in patients of a rather older age and comorbidity index needs to be revisited.
- Ovastat (treosulfan) / Medac
[VIRTUAL] LONG-TERM SAFETY AND EFFICACY OF A MYELOABLATIVE CONDITIONING REGIMEN OF REDUCED TOXICITY IN ALLOGENEIC HEMATOPOIETIC CELL TRANSPLANTATION (ePoster Area) - Feb 4, 2021 - Abstract #EBMT2021EBMT_2554;
Our real-world study confirms that alloHCT with FluTreo expands the transplant population with outcomes comparable to other myeloablative conditionings, even in secondary AML. The choice of alloHCT in patients of a rather older age and comorbidity index needs to be revisited.
- Ovastat (treosulfan) / Medac
[VIRTUAL] LONG-TERM SAFETY AND EFFICACY OF A MYELOABLATIVE CONDITIONING REGIMEN OF REDUCED TOXICITY IN ALLOGENEIC HEMATOPOIETIC CELL TRANSPLANTATION (ePoster Area) - Feb 4, 2021 - Abstract #EBMT2021EBMT_2553;
Our real-world study confirms that alloHCT with FluTreo expands the transplant population with outcomes comparable to other myeloablative conditionings, even in secondary AML. The choice of alloHCT in patients of a rather older age and comorbidity index needs to be revisited.
- Ovastat (treosulfan) / Medac
[VIRTUAL] LONG-TERM SAFETY AND EFFICACY OF A MYELOABLATIVE CONDITIONING REGIMEN OF REDUCED TOXICITY IN ALLOGENEIC HEMATOPOIETIC CELL TRANSPLANTATION (ePoster Area) - Feb 4, 2021 - Abstract #EBMT2021EBMT_2552;
Our real-world study confirms that alloHCT with FluTreo expands the transplant population with outcomes comparable to other myeloablative conditionings, even in secondary AML. The choice of alloHCT in patients of a rather older age and comorbidity index needs to be revisited.
- Ovastat (treosulfan) / Medac
[VIRTUAL] INTERNATIONAL SURVEY AND RETROSPECTIVE ANALYSIS OF 28 PATIENTS WITH IFN-Γ-RECEPTOR DEFICIENCY (Auditorium 4) - Feb 4, 2021 - Abstract #EBMT2021EBMT_2351;
In this multi-center retrospective analysis of transplant data in the largest cohort of patients with IFNGR-deficiency we have found a median time of almost 2 years between the clinical diagnosis and the curative procedure of HSCT. Although a more in-depth data analysis aiming to identify those factors related to a favorable disease/HSCT course is ongoing, overall outcomes seem to have improved considerably in the recent years.
- Ovastat (treosulfan) / Medac
[VIRTUAL] EXCELLENT TRANSPLANT SURVIVAL FOR CHILDREN WITH ADENOSINE DEAMINASE (ADA) DEFICIENCY (Auditorium 4) - Feb 4, 2021 - Abstract #EBMT2021EBMT_2343;
Pre-transplant ERT and Treo-based conditioning is a promising strategy with excellent survival and long-term disease outcome. Since 2007, alternative donor HCT is comparable to MFD HCT.
- Orencia (abatacept) / BMS, Thymoglobulin (anti-thymocyte globulin (rabbit)) / Sanofi, Actemra IV (tocilizumab) / Roche, JW Pharma
[VIRTUAL] SEROTHERAPY-FREE REGIMEN IMPROVES NON-RELAPSE MORTALITY AND EARLY IMMUNE RECOVERY AMONG THE RECIPIENTS OF ΑΒ T CELL-DEPLETED HAPLOIDENTICAL GRAFTS: RETROSPECTIVE STUDY IN CHILDHOOD LEUKEMIA (Auditorium 4) - Feb 4, 2021 - Abstract #EBMT2021EBMT_2342;
Conditioning was based on either 12Gy TBI or treosulfan. Thiotepa, fludarabine, bortezomib and rituximab were used as additional agents... Among the recipients of ab T cell-depleted grafts, replacement of rabbit ATG with non-lymphodepleting abatacept and tocilizumab immunomodulation did not compromise engraftment and GVHD control and was associated with significantly lower NRM and better immune recovery early after HSCT.
- Ovastat (treosulfan) / Medac
[VIRTUAL] TREOSULFAN- VERSUS BUSULFAN-BASED MYELOABLATIVE CONDITIONING FOR ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION IN PEDIATRIC ACUTE LYMPHOBLASTIC LEUKEMIA. A REPORT FROM THE INTERNATIONAL ALL-SCTPED FORUM TRIAL (Auditorium 4) - Feb 4, 2021 - Abstract #EBMT2021EBMT_2341;
P2/3
A Treosulfan-based conditioning results in similar outcomes as compared to a Busulfan-based regimen with low rates of TRM especially for patients with T-ALL. Clinical Trial Registry: EudraCT: 2012-003032-22; ClinicalTrials.Gov: NCT01949129
- Defitelio (defibrotide) / IRCCS San Raffaele Hospital, Jazz
[VIRTUAL] DEFIBROTIDE PROPHYLAXIS FOR VENO-OCCLUSIVE DISEASE/SINUSOIDAL OBSTRUCTION SYNDROME (VOD/SOS) AFTER HAEMATOPOIETIC CELL TRANSPLANTATION (HCT): ANALYSIS OF A MULTICENTRE, MULTINATIONAL, PROSPECTIVE, OBSERVATIONAL REGISTRY STUDY (EBMT PASS) (On-Demand Library) - Feb 4, 2021 - Abstract #EBMT2021EBMT_1904;
P=N/A, P3
VOD/SOS resolved in all cases and no VOD/SOS-related deaths occurred. The safety of defibrotide prophylaxis in the real-world setting was consistent with the known defibrotide safety profile.
- Defitelio (defibrotide) / IRCCS San Raffaele Hospital, Jazz
[VIRTUAL] DEFIBROTIDE PROPHYLAXIS FOR VENO-OCCLUSIVE DISEASE/SINUSOIDAL OBSTRUCTION SYNDROME (VOD/SOS) AFTER HAEMATOPOIETIC CELL TRANSPLANTATION (HCT): ANALYSIS OF A MULTICENTRE, MULTINATIONAL, PROSPECTIVE, OBSERVATIONAL REGISTRY STUDY (EBMT PASS) (On-Demand Library) - Feb 4, 2021 - Abstract #EBMT2021EBMT_1903;
P=N/A, P3
VOD/SOS resolved in all cases and no VOD/SOS-related deaths occurred. The safety of defibrotide prophylaxis in the real-world setting was consistent with the known defibrotide safety profile.
- Defitelio (defibrotide) / IRCCS San Raffaele Hospital, Jazz
[VIRTUAL] DEFIBROTIDE PROPHYLAXIS FOR VENO-OCCLUSIVE DISEASE/SINUSOIDAL OBSTRUCTION SYNDROME (VOD/SOS) AFTER HAEMATOPOIETIC CELL TRANSPLANTATION (HCT): ANALYSIS OF A MULTICENTRE, MULTINATIONAL, PROSPECTIVE, OBSERVATIONAL REGISTRY STUDY (EBMT PASS) (On-Demand Library) - Feb 4, 2021 - Abstract #EBMT2021EBMT_1902;
P=N/A, P3
VOD/SOS resolved in all cases and no VOD/SOS-related deaths occurred. The safety of defibrotide prophylaxis in the real-world setting was consistent with the known defibrotide safety profile.
- Defitelio (defibrotide) / IRCCS San Raffaele Hospital, Jazz
[VIRTUAL] DEFIBROTIDE PROPHYLAXIS FOR VENO-OCCLUSIVE DISEASE/SINUSOIDAL OBSTRUCTION SYNDROME (VOD/SOS) AFTER HAEMATOPOIETIC CELL TRANSPLANTATION (HCT): ANALYSIS OF A MULTICENTRE, MULTINATIONAL, PROSPECTIVE, OBSERVATIONAL REGISTRY STUDY (EBMT PASS) (On-Demand Library) - Feb 4, 2021 - Abstract #EBMT2021EBMT_1901;
P=N/A, P3
VOD/SOS resolved in all cases and no VOD/SOS-related deaths occurred. The safety of defibrotide prophylaxis in the real-world setting was consistent with the known defibrotide safety profile.
- Ovastat (treosulfan) / Medac
[VIRTUAL] LONG TERM OUTCOMES AFTER INTRABONE UNRELATED UMBILICAL CORD BLOOD TRANSPLANT IN PATIENTS WITH HEMATOLOGICAL MALIGNANCIES: A EUROCORD, CTIWP-EBMT ANALYSIS (On-Demand Library) - Feb 4, 2021 - Abstract #EBMT2021EBMT_1696;
The use of ATG-free-regimen and better supportive therapy may further improve results. The IB injection of UCB ex-vivo-expanded is attractive to enhance homing of expanded cord-blood derived stem cells.
- Ovastat (treosulfan) / Medac
[VIRTUAL] LONG TERM OUTCOMES AFTER INTRABONE UNRELATED UMBILICAL CORD BLOOD TRANSPLANT IN PATIENTS WITH HEMATOLOGICAL MALIGNANCIES: A EUROCORD, CTIWP-EBMT ANALYSIS (On-Demand Library) - Feb 4, 2021 - Abstract #EBMT2021EBMT_1695;
The use of ATG-free-regimen and better supportive therapy may further improve results. The IB injection of UCB ex-vivo-expanded is attractive to enhance homing of expanded cord-blood derived stem cells.
- Ovastat (treosulfan) / Medac
[VIRTUAL] LONG TERM OUTCOMES AFTER INTRABONE UNRELATED UMBILICAL CORD BLOOD TRANSPLANT IN PATIENTS WITH HEMATOLOGICAL MALIGNANCIES: A EUROCORD, CTIWP-EBMT ANALYSIS (On-Demand Library) - Feb 4, 2021 - Abstract #EBMT2021EBMT_1694;
The use of ATG-free-regimen and better supportive therapy may further improve results. The IB injection of UCB ex-vivo-expanded is attractive to enhance homing of expanded cord-blood derived stem cells.
- Ovastat (treosulfan) / Medac
[VIRTUAL] LONG TERM OUTCOMES AFTER INTRABONE UNRELATED UMBILICAL CORD BLOOD TRANSPLANT IN PATIENTS WITH HEMATOLOGICAL MALIGNANCIES: A EUROCORD, CTIWP-EBMT ANALYSIS (On-Demand Library) - Feb 4, 2021 - Abstract #EBMT2021EBMT_1693;
The use of ATG-free-regimen and better supportive therapy may further improve results. The IB injection of UCB ex-vivo-expanded is attractive to enhance homing of expanded cord-blood derived stem cells.
- Ovastat (treosulfan) / Medac
[VIRTUAL] IS24 Current Developments in Allogeneic Haematopoietic Stem Cell Transplantation: Recent data on treosulfan - Medac Industry Symposium (Auditorium 2) - Feb 4, 2021 - Abstract #EBMT2021EBMT_1374;
The IB injection of UCB ex-vivo-expanded is attractive to enhance homing of expanded cord-blood derived stem cells. Sponsor: Medac
- Natesto (testosterone) / Acerus, Medac, Aytu Biosci
[VIRTUAL] Trabecular Bone Score in Women With Differentiated Thyroid Cancer (On-Demand) - Feb 2, 2021 - Abstract #ENDO2021ENDO_2098;
However, lower TBS values were observed in postmenopausal women of both groups, even in those with nonsuppressive therapy. These data show that treatment with thyroid hormone in DTC can be detrimental to bone quality in postmenopausal women, regardless of whether TSH levels are maintained chronically suppressed or in the low-normal range.